Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

448.34 -1.18 (-0.26%)
Streaming Delayed Price Updated: 1:57 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
69 70 Next >
News headline image
Good technical signals and a possible breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). ↗
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
News headline image
5 Top Stocks to Buy in March ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
3 Magnificent Growth Stocks to Buy Right Now ↗
Via The Motley Fool
News headline image
Analyst Expectations For Vertex Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results ↗
 
Via Benzinga
News headline image
Vertex: Strong Sales, Stronger Pipeline ↗
Via The Motley Fool
News headline image
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
Vertex to Participate in Upcoming March Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Stocks That Could Trounce the Market in 2025 ↗
Via The Motley Fool
News headline image
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗
Via The Motley Fool
News headline image
The Ultimate Healthcare Stock to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing ↗
Via The Motley Fool
News headline image
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
News headline image
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗
Via The Motley Fool
News headline image
This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
News headline image
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish ↗
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller. 
Via Stocktwits
News headline image
Markets Steady, Positive; Q4 Earnings Keep Rolling ↗
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline... 
Via Talk Markets
Topics Government Stocks / Equities World Trade
News headline image
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript ↗
VRTX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Vertex's Revenue Surges but EPS Slips ↗
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the... 
Via StockStory
News headline image
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge? ↗
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain. 
Via Benzinga
News headline image
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings ↗
 
Via Benzinga
News headline image
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst ↗
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports. 
Via Benzinga
Topics World Trade
News headline image
Earnings Scheduled For February 10, 2025 ↗
 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.